BrainStorm Cell Therapeutics
Update in progressBCLI (OTC Markets OTCQB)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Brainstorm Cell Therapeutics is a biotechnology company developing autologous cellular therapies for neurodegenerative diseases. Its NurOwn platform uses a patient’s own bone marrow–derived mesenchymal stem cells cultured to secrete neurotrophic factors that modulate neuroinflammation and support neuronal survival and function. NurOwn has completed Phase IIIb for ALS and Phase II for progressive MS, with research in Alzheimer's and other diseases. Founded 2000, based in New York.
Company score
- Sentiment
- 0.24
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.26
- Governance
- 0.10
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.17
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketOTC Markets OTCQB (OQB)
- LocationUnited States
- CEOMr. Chaim Lebovits
- Founded2000
- Employees19
- Websitewww.brainstorm-cell.com
Identifiers
- ISINUS10501E2019
- FIGIBBG000FR6HQ1
- LEI529900ULKWCLO3ZHXL41
- CUSIP10501E102
- CIK0001137883